Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 11, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/jpm11070651
Keywords
LAG3; soluble immune checkpoints; head and neck cancer; immunotherapy
Funding
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [17432, RM118164277B5F2A, RM1181643132016E]
Ask authors/readers for more resources
Through the evaluation of specific soluble immune checkpoints, particularly sLAG3, it can help identify patients with poor prognosis or resistance to treatment, and may lead to the development of novel targeted strategies.
Unresectable recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has a very poor prognosis. Soluble immune checkpoints (sICs) are circulating proteins that result from the alternative splicing of membrane proteins and can modulate the immune response to cancer cells. The aim of our pilot study was to determine the possible role of a comprehensive evaluation of sICs in the classification of prognosis and response to treatment in patients with advanced disease. We evaluated several sICs (CD137, CTLA-4, PD-1, PD-L1, PD-L2, TIM3, LAG3, GITR, HVEM, BTLA, IDO, CD80, CD27, and CD28) from peripheral blood at baseline and investigated the association with clinical characteristics and outcomes. A high baseline soluble LAG3 (sLAG3 > 377 pg/mL) resulted in an association with poor PFS and OS (p = 0.047 and p = 0.003, respectively). Moreover, sLAG3 emerged as an independent prognostic factor using an MVA (p = 0.005). The evaluation of sICs, in particular sLAG3, may be relevant for identifying patients with worse prognoses, or resistance to treatments, and may lead to the development of novel targeted strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available